009290.Ks
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of prescription drugs and related healthcare products.
The company maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.46, indicating a moderate reliance on debt financing. However, the company's liquidity position is assessed as medium, with a current ratio of 1.36, suggesting it has sufficient short-term assets to cover its short-term liabilities, but not with a large margin of safety. The company's free cash flow is positive at 8.5 billion KRW, but its capital expenditures are negative at -26.4 billion KRW, indicating a reduction in investment in long-term assets.
In terms of profitability, the company's return on equity (ROE) is 3.2%, and its return on assets (ROA) is 1.59%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, suggesting that the company is not generating particularly high returns relative to its equity or total assets.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification reported. This lack of diversification may expose the company to higher risks if market conditions in its primary operating region change.
The company's growth trajectory appears to be modest, with no specific numeric deltas provided for the current or next fiscal year. However, the company's operating income and net income have shown positive values, indicating a stable performance in recent periods.
The company's risk profile is characterized by a medium liquidity risk and a low dilution risk. The key risk flag is the negative net cash position after subtracting total debt, which could indicate potential liquidity constraints. The company has not disclosed any significant dilution sources in its recent filings, and the dilution risk is assessed as low.
Recent events, as disclosed in the company's financial filings, include a reduction in capital expenditures and a negative net cash position. These developments may signal a strategic shift or financial constraints that could impact the company's future performance.
- The company has a moderate debt-to-equity ratio, indicating a balanced capital structure.
- The company's ROE and ROA are below typical industry benchmarks, suggesting lower profitability.
- The company's revenue is not diversified across multiple segments or geographic regions.
- The company's liquidity position is assessed as medium, with a current ratio of 1.36.
- The company's risk profile is characterized by medium liquidity risk and low dilution risk.
- The company has not disclosed significant dilution sources in its recent filings.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 009290.KS Market data — financials · 2026-05-26
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
4 tracked-field change(s) detected vs prior analysis; max severity: medium.
- Dilution risk— → lowlow
- Liquidity risk— → mediumlow
- Activity— → Pharmaceuticals & Medical Researchmedium
- Economic sector— → Healthcaremedium